The deal revolves around a drug Sobi claimed could become the “therapy of choice” for people whose gout symptoms persist ...

Fresh off a $153 million series E round, Arthrosi Therapeutics is skipping an IPO route and is instead being bought up for a ...

Milestone Pharmaceuticals won FDA approval for a new nasal-spray medicine to treat episodes of paroxysmal supraventricular ...

In recent years, scientists have increasingly turned their attention to older, affordable drugs to explore whether they offer benefits beyond their original purpose. Colchicine, a cheap and widely ...

WASHINGTON, DC — Use of sodium-glucose cotransporter-2 inhibitors (SGLT2i) reduced the need for urate-lowering therapy (ULT) and gout flare therapies in people who had both type 2 diabetes (T2D) and ...

For gout pain that does not respond to conventional therapies, patients’ only remaining option is a drug from Amgen. But this biologic medicine introduces the same problem facing every therapeutic ...

Due to a policy decision in 2010 by the U.S. Food and Drug Administration (FDA), the price of a prescription for the therapeutic gout drug colchicine increased nearly 16-fold from $11.25 in 2009 to ...

October 2, 2012 — New gout guidelines from the American College of Rheumatology are meant to improve gout management by providing clinicians with clear, readily implemented guidance on urate-lowering ...

Cuts uric acid levels in combination with standard drug Combination of drugs more effective than standard care Plans to start 200-patient study in early 2011 Sept 16 (Reuters) - BioCryst ...

A gout drug that Swedish Orphan Biovitrim picked up in a $100 million deal has achieved the main goal in two Phase 3 studies, showing statistically significant reductions blood levels of the protein ...

(Reuters) - An independent panel of advisers to the U.S. Food and Drug Administration on Friday voted 10-4 in favor of approving AstraZeneca Plc's gout drug. All 10 who backed the drug, lesinurad, ...

BARCELONA, Spain—The gout drug allopurinol on top of usual care does not improve cardiovascular outcomes in patients over age 60 who do not have gout, the ALL-HEART trial confirms. The long-running ...